Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
79 hedge funds and large institutions have $224M invested in Progenics Pharmaceuticals Inc in 2013 Q2 according to their latest regulatory filings, with 79 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
96% less call options, than puts
Call options by funds: $81K | Put options by funds: $1.83M
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
U
76
UBS
Zurich,
Switzerland
| $8K | +$7.85K | +1,750 | New |
|
77
BlackRock
New York
| $7K | +$6.72K | +1,497 | New |
|
|
TRCT
78
Tower Research Capital (TRC)
New York
| $1K | +$897 | +200 | New |
|
79
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.35K | +300 | New |
|
PGNX Hedge Fund Activity: Q2 2013 in Review
79 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q2 2013, worth a combined $224M.
Buyers outnumbered sellers: 79 funds opened new PGNX positions and 0 closed out — a net gain of 79 holders — while 0 added to existing stakes and 0 trimmed.
- 79 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $224M of Progenics Pharmaceuticals Inc stock for Q2 2013.
- 79 funds opened new Progenics Pharmaceuticals Inc positions in Q2 2013 and 0 closed out, a net change of +79 holders.
Based on aggregated 13F filings for Q2 2013.